atorvastatin calcium trihydrate
Modify Date: 2024-01-04 22:58:53
atorvastatin calcium trihydrate structure
|
Common Name | atorvastatin calcium trihydrate | ||
|---|---|---|---|---|
| CAS Number | 344423-98-9 | Molecular Weight | 1209.388 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C66H74CaF2N4O13 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07, GHS08 |
Signal Word | Danger | |
Use of atorvastatin calcium trihydrateAtorvastatin is used primarily for lowering blood cholesterol and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.Atorvastatin is also used for the treatment of dyslipidemia. |
| Name | atorvastatin calcium trihydrate |
|---|---|
| Synonym | More Synonyms |
| Molecular Formula | C66H74CaF2N4O13 |
|---|---|
| Molecular Weight | 1209.388 |
| Exact Mass | 1208.484619 |
| PSA | 256.93000 |
| LogP | 9.91090 |
| Water Solubility | Very slightly soluble in water, slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. |
| Symbol |
GHS07, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H319-H360D |
| Precautionary Statements | P201-P280-P305 + P351 + P338-P308 + P313-P337 + P313 |
| Hazard Codes | T |
| Risk Phrases | 61-36 |
| Safety Phrases | 53-26-45 |
| RIDADR | NONH for all modes of transport |
|
Statins demonstrate a broad anti-cytomegalovirus activity in vitro in ganciclovir-susceptible and resistant strains.
J. Med. Virol. 87(1) , 141-53, (2014) Vasculoprotective and cholesterol-lowering properties are hallmarks of statins. Recently, statins have been found to exhibit antiviral activity. Little is known about the potential of statins against ... |
|
|
Dehydroepiandrosterone sulfate, a useful endogenous probe for evaluation of drug-drug interaction on hepatic organic anion transporting polypeptide (OATP) in cynomolgus monkeys.
Drug Metab. Pharmacokinet. 30(2) , 198-204, (2015) Since drug-drug interaction (DDI) can affect organic anion-transporting polypeptide (OATP) and cause clinical events, prediction of such DDI is important in early clinical development. Although statin... |
|
|
Legumain expression, activity and secretion are increased during monocyte-to-macrophage differentiation and inhibited by atorvastatin.
Biol. Chem. 396(1) , 71-80, (2014) Macrophages express several lysosomal cysteine proteases such as cathepsins and legumain. In this study, we assessed the expression, activity and secretion of legumain in cellular models of monocytes/... |
| atorvastatin calcium trihydrate |
| 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt, (βR,δR)-, hydrate (2:1:3) |
| Torvast |
| Atorvastatin Calcium Salt Trihydrate |
| Atorvastatin hemicalcium salt sesquihydrate |
| Lipitor |
| 1H-Pyrrole-1-heptanoicacid, 2-(4-fluorophenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-,calcium salt, hydrate (2:1:3), (bR,dR)- |
| Calcium (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate hydrate (1:2:3) |
| Sortis |
| Totalip |